Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Ser49Gly of beta1-adrener… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.

Artikel i vetenskaplig tidskrift
Författare Yvonne Magnusson
Malin Levin
Robert Eggertsen
Ernst Nyström
Reza Mobini
Maria Schaufelberger
Bert Andersson
Publicerad i Clinical pharmacology and therapeutics
Volym 78
Nummer/häfte 3
Sidor 221-31
ISSN 0009-9236
Publiceringsår 2005
Publicerad vid Wallenberglaboratoriet
Hjärt-kärlinstitutionen
Institutionen för samhällsmedicin, Avdelningen för allmänmedicin
Institutionen för invärtesmedicin, Avdelningen för internmedicin
Sidor 221-31
Språk en
Länkar dx.doi.org/10.1016/j.clpt.2005.06.0...
Ämnesord Adrenergic beta-Antagonists, administration & dosage, therapeutic use, Aged, Amino Acid Substitution, Cardiomyopathy, Dilated, drug therapy, genetics, mortality, Codon, Cohort Studies, DNA, genetics, Dose-Response Relationship, Drug, Female, Genotype, Glycine, Humans, Male, Middle Aged, Polymorphism, Genetic, Prospective Studies, Receptors, Adrenergic, beta-1, drug effects, genetics, Serine, Survival Rate, Treatment Outcome
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

OBJECTIVE: Our objective was to evaluate the influence of polymorphisms at codons 49 and 389 of the beta1-adrenergic receptor (beta1-AR) on the response to beta-blockers and outcome in patients with dilated cardiomyopathy. METHODS: We genotyped both codons of the beta1-AR in 375 patients with dilated cardiomyopathy and 492 control subjects. RESULTS: Neither of the polymorphisms was associated with susceptibility for dilated cardiomyopathy. In a retrospective analysis of patients receiving beta-blockers, there was a significant association between long-term survival rate and codon 49 (P = .014) but not codon 389 (P = .08). Despite a similar mean heart rate (69 beats/min), patients with the Ser49 genotype tended to have higher doses of beta-blockade compared with Gly49 carriers (P = .065). In patients receiving a low dose of beta-blockade (< or = 50% of targeted full dose), the 5-year mortality rate was lower among Gly49 carriers than Ser49 patients (risk ratio [RR], 0.24; 95% confidence interval [CI], 0.07-0.80; P = .020). In patients receiving high doses of beta-blockers, there was no significant difference in outcome between genotypes (P = .20), which was attributable to a better outcome for Ser49 patients treated with a high dose of beta-blockade as compared with a low dose. Gly49 carriers had a similar survival rate with different doses of beta-blockers. With low-dose beta-blockers, both codon 49 (RR, 0.26; 95% CI, 0.08-0.89; P = .029) and codon 389 (RR, 2.42; 95% CI, 1.04-5.63, P = .039) were related to 5-year mortality rate. CONCLUSION: In patients with heart failure, the influence of codon 49 on the outcome and effect of beta-blockers appeared to be more pronounced than that of codon 389. The more common Ser49Ser genotype responded less beneficially to beta-blockade and would motivate genotyping to promote higher doses for the best outcome effect.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://gu.se/forskning/publikation/?languageId=100000&disableRedirect=true&returnUrl=http%3A%2F%2Fgu.se%2Fenglish%2Fresearch%2Fpublication%2F%3Fprint%3Dtrue%26publicationId%3D65467&publicationId=65467
Utskriftsdatum: 2020-03-31